Safety and efficacy of heated chemotherapy given during surgery in management of gall bladder cancer
Not Applicable
Completed
- Conditions
- Health Condition 1: null- Carcinoma gall bladder
- Registration Number
- CTRI/2018/02/011879
- Lead Sponsor
- I
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 45
Inclusion Criteria
patients with gall bladder carcinoma undergoing surgery.
Exclusion Criteria
Patients found to have widespread metastases( not amneable to cytoreduction) during surgery.
Unresectable disease.
Unfit for surgery.
Developing hemodynamic instability during the procedure.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To study any intraoperative or postoperative complications occuring in patients of gall bladder carcinoma undergoing surgery.Timepoint: on follow up at 1 month
- Secondary Outcome Measures
Name Time Method To follow up patietns of gall bladder carcinoma treated with surgery and HIPEC at 3 and 6 months to detect locoregionaln recurrenceTimepoint: follow up at 3 and 6 months
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie HIPEC's efficacy in gall bladder carcinoma?
How does hyperthermic intra peritoneal chemotherapy compare to systemic chemotherapy for gall bladder cancer?
Which biomarkers are associated with response to HIPEC in gall bladder carcinoma patients?
What are the common adverse events of HIPEC in gall bladder cancer treatment and how are they managed?
Are there combination therapies involving HIPEC and targeted agents for gall bladder carcinoma?